These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 4061965)

  • 1. The anticholinergic side effects of disopyramide and controlled-release disopyramide.
    Teichman S
    Angiology; 1985 Nov; 36(11):767-71. PubMed ID: 4061965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disopyramide-pyridostigmine: report of a beneficial drug interaction.
    Teichman SL; Fisher JD; Matos JA; Kim SG
    J Cardiovasc Pharmacol; 1985; 7(1):108-13. PubMed ID: 2580128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disopyramide-pyridostigmine interaction: selective reversal of anticholinergic symptoms with preservation of antiarrhythmic effect.
    Teichman SL; Ferrick A; Kim SG; Matos JA; Waspe LE; Fisher JD
    J Am Coll Cardiol; 1987 Sep; 10(3):633-41. PubMed ID: 3624669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disopyramide: clinical indications, pharmacokinetics and laboratory assessment.
    Taylor EH; Pappas AA
    Ann Clin Lab Sci; 1986; 16(4):289-95. PubMed ID: 2427003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacologic evaluation of standard and controlled-release disopyramide.
    Siddoway LA; Barbey JT; Roden DM; Woosley RL
    Angiology; 1987 Feb; 38(2 Pt 2):184-7. PubMed ID: 3103492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias.
    Heel RC; Brogden RN; Speight TM; Avery GS
    Drugs; 1978 May; 15(5):331-68. PubMed ID: 350555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of disopyramide by arrhythmia specialists after Cardiac Arrhythmia Suppression Trial: patient selection and initial outcome.
    Prystowsky EN; Waldo AL; Fisher JD
    Am Heart J; 1991 May; 121(5):1571-82. PubMed ID: 2017999
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antiarrhythmic treatment of ventricular ectropic arrhythmies with Disopyramide].
    Olbermann M; Just H; Guckenbiehl H; Lang KF
    Med Klin; 1976 Apr; 71(14):593-8. PubMed ID: 57567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum drug concentrations and adverse effects in cardiac patients after administration of a new controlled-release disopyramide preparation.
    Zema MJ
    Ther Drug Monit; 1984; 6(2):192-8. PubMed ID: 6740739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antiarrhythmic effect of disopyramide in ventricular extrasystole and auricular fibrillation].
    Breithardt G; Haerten K; Seipel L
    Z Kardiol; 1976 Aug; 65(8):713-23. PubMed ID: 61664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics and effects of an oral sustained-release preparation of disopyramide prescribed for patients undergoing maintenance hemodialysis.
    Kaji T; Nojima Y; Arisaka H; Naruse T
    Blood Purif; 2000; 18(1):55-8. PubMed ID: 10686443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias.
    Ekelund LG; Nilsson E; Walldius G
    Eur J Clin Pharmacol; 1986; 29(6):673-7. PubMed ID: 3519236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfer from immediate-release disopyramide to controlled-release disopyramide.
    DiPersio DM; Chow MS
    Angiology; 1987 Feb; 38(2 Pt 2):188-91. PubMed ID: 3103493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disopyramide.
    Koch-Weser J
    N Engl J Med; 1979 Apr; 300(17):957-62. PubMed ID: 431563
    [No Abstract]   [Full Text] [Related]  

  • 15. Disopyramide-induced hypoglycemia: case report and review of the literature.
    Cacoub P; Deray G; Baumelou A; Grimaldi A; Soubrie C; Jacobs C
    Fundam Clin Pharmacol; 1989; 3(5):527-35. PubMed ID: 2691378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disopyramide-induced urinary retention. Report of nine cases and review of the literature.
    Danziger LH; Horn JR
    Arch Intern Med; 1983 Sep; 143(9):1683-86. PubMed ID: 6615089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative absorption of disopyramide as determined by liquid chromatography following acute administration of standard capsules and controlled-release tablets.
    Graffner C; Lagerström PO; Lundborg PN; Rönn OF
    Int J Clin Pharmacol Ther Toxicol; 1981 Sep; 19(9):414-9. PubMed ID: 7298249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of serum concentrations of disopyramide and its metabolite mono-N-dealkyldisopyramide on the anticholinergic side effects associated with disopyramide.
    Tsuchishita Y; Fukumoto K; Kusumoto M; Ueno K
    Biol Pharm Bull; 2008 Jul; 31(7):1368-70. PubMed ID: 18591776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical studies of the antiarrhythmic efficacy of disopyramide phosphate (Norpace) (author's transl)].
    Smith WS
    Herz; 1978 Dec; 63(36):399-406. PubMed ID: 95482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from intravenous to oral slow-release disopyramide in acute myocardial infarction.
    Zannad F; Royer-Morrot MJ; Zakari I; Sadoul N; Royer RJ
    Fundam Clin Pharmacol; 1987; 1(3):219-24. PubMed ID: 3428841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.